Effect of psoriasis treatment on plasma concentrations of metalloproteinase‐1 and tissue inhibitor of metalloproteinases‐1
- 21 April 2005
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 19 (4) , 418-421
Abstract
Aim The aim of this study was to evaluate the effect of psoriasis treatment on plasma concentrations of metalloproteinase‐1 (MMP‐1) and tissue inhibitor of metalloproteinases‐1 (TIMP‐1) with respect to disease severity.Methods MMP‐1 and TIMP‐1 were measured using an enzyme immunoassay in plasma of 32 patients before and after topical treatment. Data were analysed with respect to baseline values of the Psoriasis Area and Severity Index (PASI).Results Baseline plasma concentrations of both TIMP‐1 and MMP‐1 (1487 ± 102 and 21.0 ± 2.5 ng/mL, respectively) were significantly higher (P = 0.02 and 0.03, respectively) than normal. Both TIMP‐1 and MMP‐1 decreased significantly after completion of treatment to values similar to normal (1112 ± 127 and 11.3 ± 1.3 ng/mL, respectively). There was a significant positive correlation (r = 0.522) between baseline PASI and TIMP‐1 values. Significant differences were observed between baseline TIMP‐1 concentrations in groups with PASI < 15 and PASI > 20. Baseline values (1697 ± 162 ng/mL) in patients with severe course of the disease (PASI > 20) were significantly elevated in comparison to normal values. Treatment caused a decrease in TIMP‐1 plasma concentrations in all groups, but a significant difference was noted only in patients with pretreatment PASI > 20. Baseline MMP‐1 concentrations exceeded significantly normal values only in patients with PASI < 15 (27.2 ± 6.3 ng/mL) and 15–20 (18.4 ± 1.4 ng/mL). Treatment caused a significant decrease in MMP‐1‐values in all groups to levels similar to normal.Conclusions Our results confirm the role of TIMP‐1 and MMP‐1 in the pathogenesis of psoriasis. Pretreatment plasma TIMP‐1 increased whereas MMP‐1 decreased in patients with a more severe course of the disease. However, successful treatment causes normalization of these plasma protein concentrations irrespective of psoriasis baseline activity.Keywords
This publication has 24 references indexed in Scilit:
- Rosiglitazone Inhibits Proliferation, Motility, and Matrix Metalloproteinase Production in KeratinocytesJournal of Investigative Dermatology, 2004
- Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblingsRheumatology, 2003
- Plasma transforming growth factor β1as a biomarker of psoriasis activity and treatment efficacyBiomarkers, 2003
- Metalloelastase (MMP‐12) and 92‐kDa gelatinase (MMP‐9) as well as their inhibitors, TIMP‐1 and ‐3, are expressed in psoriatic lesionsExperimental Dermatology, 2001
- Basement Membrane Alterations in Psoriasis are Accompanied by Epidermal Overexpression of MMP-2 and its Inhibitor TIMP-2Journal of Investigative Dermatology, 2000
- Relationship Between Cell-Associated Matrix Metalloproteinase 9 and Psoriatic Keratinocyte GrowthJournal of Investigative Dermatology, 2000
- Elevation of Serum Levels of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-1 and Type IV Collagen, and Plasma Levels of Metalloproteinase-9 in Polycystic Kidney DiseaseAmerican Journal of Nephrology, 2000
- Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitorsBritish Journal of Dermatology, 1999
- The 72-kDa and the 92-kDa gelatinases, but not their inhibitors TIMP-1 and TIMP-2, are expressed in early psoriatic lesionsExperimental Dermatology, 1997
- Differential localization of TGF-β-precursor isotypes in psoriatic human skinJournal of Dermatological Science, 1996